bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH, together with Robert Bosch Ven\u00adtures, LBBW Ven\u00adtures, and a pri\u00advate busi\u00adness angel, has invested in Applyo Jena GmbH as part of a Series A financ\u00ading round. The fund\u00ading will sup\u00adport the com\u00adpa\u00adny\u2019s con\u00adtin\u00adued expan\u00adsion in the mol\u00ade\u00adc\u00adu\u00adlar diag\u00adnos\u00adtics sec\u00adtor and ini\u00adti\u00adate prod\u00aduct devel\u00adop\u00adment for phar\u00adma\u00adceu\u00adti\u00adcal applications.<\/p>\n
Founded in 2021 and based in Jena, Applyo has devel\u00adoped a unique and patented tech\u00adnol\u00adogy for the lyophiliza\u00adtion of reagent mix\u00adtures into so-called \u2018beads\u2019\u2014miniature freeze-dried spheres that pre\u00adserve even highly active com\u00adpo\u00adnents such as enzymes in an active state. Upon dis\u00adso\u00adlu\u00adtion, these com\u00adpo\u00adnents are fully reac\u00adti\u00advated. Applyo\u2019s inno\u00adva\u00adtion addresses a crit\u00adi\u00adcal chal\u00adlenge in the rapidly grow\u00ading point-of-care (POC) diag\u00adnos\u00adtics mar\u00adket: con\u00adven\u00adtional POC tests often depend on sen\u00adsi\u00adtive bio\u00adlog\u00adi\u00adcal reagents that require con\u00adtin\u00adu\u00adous refrig\u00ader\u00ada\u00adtion and typ\u00adi\u00adcally have a shelf life of only three to six months. By elim\u00adi\u00adnat\u00ading the need for a cold chain and sig\u00adnif\u00adi\u00adcantly extend\u00ading prod\u00aduct shelf life, Applyo\u2019s tech\u00adnol\u00adogy has the poten\u00adtial to trans\u00adform the industry.<\/p>\n
The point-of-care diag\u00adnos\u00adtics mar\u00adket has expe\u00adri\u00adenced sub\u00adstan\u00adtial growth, a trend accel\u00ader\u00adated by the COVID-19 pan\u00addemic, which drove diag\u00adnos\u00adtic test\u00ading closer to the patient, includ\u00ading in emer\u00adgency rooms. In par\u00adal\u00adlel, the global freeze-dry\u00ading mar\u00adket for phar\u00adma\u00adceu\u00adti\u00adcal and biotech prod\u00aducts reached a value of USD 6 bil\u00adlion in 2023 and is pro\u00adjected to grow at a rate of 8% annu\u00adally through 2028.<\/p>\n
Applyo suc\u00adcess\u00adfully com\u00adpleted the devel\u00adop\u00adment of its tech\u00adnol\u00adogy and began com\u00admer\u00adcial sales in mid-2023. The com\u00adpany has already secured major cus\u00adtomers and is in advanced nego\u00adti\u00ada\u00adtions with lead\u00ading indus\u00adtry dis\u00adtrib\u00adu\u00adtors. Fur\u00adther\u00admore, Applyo has estab\u00adlished a highly effi\u00adcient and scal\u00adable pro\u00adduc\u00adtion process, while main\u00adtain\u00ading a bead qual\u00adity that is unbeat(d)able com\u00adpared to cur\u00adrent indus\u00adtry standards.<\/p>\n
While in a first clos\u00ading at the end of 2024, Robert Bosch Ven\u00adture Cap\u00adi\u00adtal and LBBW Ven\u00adture Cap\u00adi\u00adtal invested into Applyo, bm|t com\u00adpleted the Series A financ\u00ading round in a sec\u00adond clos\u00ading, along\u00adside a pri\u00advate busi\u00adness angel. The invest\u00adment will pri\u00admar\u00adily fuel Applyo\u2019s growth in the diag\u00adnos\u00adtics mar\u00adket and sup\u00adport the com\u00adpa\u00adny\u2019s entry into the phar\u00adma\u00adceu\u00adti\u00adcal sector.<\/p>\n
Dr. Ingo Rame\u00adsohl, Man\u00adag\u00ading Direc\u00adtor of Bosch Ven\u00adtures, com\u00admented: \u201cApplyo\u2019s pio\u00adneer\u00ading approach opens up excit\u00ading oppor\u00adtu\u00adni\u00adties for point-of-care sys\u00adtem providers to trans\u00adport and store sen\u00adsi\u00adtive reagents and enzymes with\u00adout the need for con\u00adtin\u00adu\u00adous cold chains\u2014enabling more sus\u00adtain\u00adable sup\u00adply chains.\u201d<\/p>\n
Katja Butz\u00admann, Man\u00adag\u00ading Direc\u00adtor of bm|t, added: \u201cWith Applyo, we are invest\u00ading in a com\u00adpany with an out\u00adstand\u00ading tech\u00adno\u00adlog\u00adi\u00adcal edge and sig\u00adnif\u00adi\u00adcant growth poten\u00adtial. The found\u00ading team, with deep exper\u00adtise in mol\u00ade\u00adc\u00adu\u00adlar biol\u00adogy and prior expe\u00adri\u00adence at indus\u00adtry lead\u00aders such as Alere and Abbott, brings exten\u00adsive know-how and a strong track record in devel\u00adop\u00ading and com\u00admer\u00adcial\u00adiz\u00ading diag\u00adnos\u00adtic tech\u00adnolo\u00adgies. With its inno\u00adv\u00ada\u00adtive approach and strong indus\u00adtry part\u00adner\u00adships, Applyo is posi\u00adtioned to rev\u00ado\u00adlu\u00adtion\u00adize point-of-care diag\u00adnos\u00adtics and phar\u00adma\u00adceu\u00adti\u00adcal man\u00adu\u00adfac\u00adtur\u00ading. At the same time, Applyo strength\u00adens the inno\u00adva\u00adtion ecosys\u00adtem in Thuringia, par\u00adtic\u00adu\u00adlarly in the Jena region.\u201d<\/p>\n
Applyo Jena GmbH spe\u00adcial\u00adizes in the lyophiliza\u00adtion of bio\u00adlog\u00adi\u00adcal reagents into con\u00adt\u00ada\u00adm\u00adi\u00adna\u00adtion-free beads, offer\u00ading solu\u00adtions that elim\u00adi\u00adnate the need for a cold chain and extend the shelf life of diag\u00adnos\u00adtic and phar\u00adma\u00adceu\u00adti\u00adcal prod\u00aducts. With its inno\u00adv\u00ada\u00adtive tech\u00adnol\u00adogy and strong indus\u00adtry part\u00adner\u00adships, Applyo is posi\u00adtioned to rev\u00ado\u00adlu\u00adtion\u00adize point-of-care diag\u00adnos\u00adtics and phar\u00adma\u00adceu\u00adti\u00adcal man\u00adu\u00adfac\u00adtur\u00ading.\u200b Fur\u00adther infor\u00adma\u00adtion: www.applyo-jena.com<\/a><\/p>\n bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH (bm|t), based in Erfurt, is the lead\u00ading ven\u00adture cap\u00adi\u00adtal and pri\u00advate equity firm in Thuringia. bm|t cur\u00adrently man\u00adages twelve funds with a total vol\u00adume of approx\u00adi\u00admately EUR 445 mil\u00adlion, invest\u00ading in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies across nearly all sec\u00adtors and stages of cor\u00adpo\u00adrate development\u2014from start-up and growth phases to suc\u00adces\u00adsion sit\u00adu\u00ada\u00adtions. Fur\u00adther infor\u00adma\u00adtion: www.bm\u2011t.de<\/a>\u200b<\/p>\n Robert Bosch Ven\u00adture Cap\u00adi\u00adtal (RBVC), known as Bosch Ven\u00adtures, is the cor\u00adpo\u00adrate ven\u00adture cap\u00adi\u00adtal com\u00adpany of the Bosch Group. Since its found\u00ading in 2007, RBVC has invested glob\u00adally in inno\u00adv\u00ada\u00adtive start-ups across all stages of devel\u00adop\u00adment, focus\u00ading on tech\u00adnolo\u00adgies in the fields of automa\u00adtion, elec\u00adtri\u00adfi\u00adca\u00adtion, cli\u00admate, and health tech.\u200b Fur\u00adther infor\u00adma\u00adtion: www.bosch.ventures<\/a><\/p>\n LBBW Ven\u00adture Cap\u00adi\u00adtal (LBBW VC) is an inde\u00adpen\u00addent sub\u00adsidiary of Lan\u00addes\u00adbank Baden-W\u00fcrt\u00adtem\u00adberg, founded in 1998. LBBW VC invests in early-stage, dis\u00adrup\u00adtive IT and life sci\u00adence com\u00adpa\u00adnies across the DACH region, with a focus on seed and Series A financ\u00ading rounds. Fur\u00adther infor\u00adma\u00adtion: www.lbbwvc.de<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" bm|t, together with Robert Bosch Ven\u00adtures, LBBW Ven\u00adtures, and a pri\u00advate busi\u00adness angel, has invested in Applyo Jena GmbH as part of a Series A financ\u00ading round.<\/p>\n","protected":false},"author":2,"featured_media":16979,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[262],"tags":[176,177,210,159,168,171,175,174],"class_list":["post-16981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2025-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-startup-fonds-en","tag-thuringia","tag-thuringia-growth-fund","tag-wbf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/16981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=16981"}],"version-history":[{"count":2,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/16981\/revisions"}],"predecessor-version":[{"id":16983,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/16981\/revisions\/16983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/16979"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=16981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=16981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=16981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}About the Investors<\/strong><\/h4>\n